Eli Lilly (LLY) Forms BioCritica for Further Xigris Development
Tweet Send to a FriendGet Alerts LLY Hot Sheet
Price: $55.90 -0.07%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3.5%
EPS Growth %: +23.9%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3.5%
EPS Growth %: +23.9%
Trade LLY Now!
Eli Lilly and Company (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc.
BioCritica will initially focus on the continued U.S. development and commercialization of Xigris (drotrecogin alfa (activated)), Lilly's medicine for severe sepsis. As part of a licensing agreement, BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly.
Financial terms of the deal were not disclosed.
BioCritica is a newly-formed and privately-held biotechnology company.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BioCritica will initially focus on the continued U.S. development and commercialization of Xigris (drotrecogin alfa (activated)), Lilly's medicine for severe sepsis. As part of a licensing agreement, BioCritica will acquire the U.S. development and commercialization rights to Xigris and will also receive the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly.
Financial terms of the deal were not disclosed.
BioCritica is a newly-formed and privately-held biotechnology company.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Santarus (SNTS) to Present Additional Data on UCERIS
- U.S. SEC Appoints Lona Nallengara as Chief of Staff; Keith Higgins as Corp. Finance Director
- Novo Nordisk (NVO) Reports Positive Results from Paradigm 2
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
